Literature DB >> 9878027

Crucial role of FcgammaRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera.

M E Rodriguez1, W L van der Pol, L A Sanders, J G van de Winkel.   

Abstract

Immunoglobulin G (IgG)-mediated phagocytosis by polymorphonuclear leukocytes (PMNL) constitutes the main defense against Streptococcus pneumoniae. Two leukocyte IgG receptors, FcgammaRIIa and FcgammaRIIIb, are constitutively expressed on PMNL. Blocking experiments showed FcgammaRIIa is crucial for opsonophagocytosis of serum-opsonized S. pneumoniae. The biallelic, genetically determined FcgammaRIIa polymorphism (FcgammaRIIa-R131 vs. IIa-H131) determines the capacity of IgG2-mediated phagocytosis via this receptor. Comparative studies with PMNL from donors either homozygous for FcgammaRIIa-R131 or IIa-H131 showed the latter had higher phagocytic capacity. These results were confirmed in FcgammaRIIa-R131- and FcgammaRIIa-H131-transfected IIA1.6 cells. The performance of FcgammaRIIa-transfected cells in S. pneumoniae phagocytosis was validated using sera from adults and children. Serum-induced phagocytic activity depended mainly on anti-pneumococcal IgG2 antibodies. Results obtained with PMNL and IIA1.6 cells showed high correlation (r=0.94; P<.001), and support that FcgammaRIIa transfectants are a good alternative to PMNL as effector cells in opsonophagocytosis assays.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878027     DOI: 10.1086/314603

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Immunoglobulin A-mediated protection against Bordetella pertussis infection.

Authors:  S M Hellwig; A B van Spriel; J F Schellekens; F R Mooi; J G van de Winkel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Neutrophil responses to CRP are not dependent on polymorphism of human FcgammaRIIA (R131H).

Authors:  J A Rodríguez; K B Bodman-Smith; J G Raynes
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

Review 3.  Human immunoglobulin allotypes: possible implications for immunogenicity.

Authors:  Roy Jefferis; Marie-Paule Lefranc
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

4.  Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.

Authors:  W T Jansen; M Väkeväinen-Anttila; H Käyhty; M Nahm; N Bakker; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Bordetella parapertussis survives the innate interaction with human neutrophils by impairing bactericidal trafficking inside the cell through a lipid raft-dependent mechanism mediated by the lipopolysaccharide O antigen.

Authors:  Juan Gorgojo; Yanina Lamberti; Hugo Valdez; Eric T Harvill; Maria Eugenia Rodríguez
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

6.  Evaluation of human FcgammaRIIA (CD32) and FcgammaRIIIB (CD16) polymorphisms in Caucasians and African-Americans using salivary DNA.

Authors:  R C van Schie; M E Wilson
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

7.  Polymorphism of the Fcgamma receptor IIA and malaria morbidity.

Authors:  Erika Martins Braga; Kézia Katiani Gorza Scopel; Natália Tiemi Komatsu; Mônica da Silva-Nunes; Marcelo Urbano Ferreira
Journal:  J Mol Genet Med       Date:  2005-07-28

8.  Modulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharide.

Authors:  Tamika Burns; Zhaojing Zhong; Michael Steinitz; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

10.  Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro.

Authors:  A E Tebo; P G Kremsner; A J F Luty
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.